| August 23, 2012 | ISSUE NUMBER 265 VOL 8 |
Special Report
Paul Ryan and Pharma: The Inside Story
Since Paul Ryan was named the Republican VP candidate last week, all hell has broken loose. What is causing all this instant 'intensity'? It appears to revolve entirely around Ryan's personality and, specifically, his views on one issue… Medicare. Tom Norton reports
...Read more
Advertisement
Pharmaceutical companies are effecting a paradigm shift in their focus towards emerging markets driven by the growing economies of these markets and the steady decline of growth opportunities in the developed markets. Varied demography, varied government spending on health and differences in the regulatory environments in individual countries of the emerging markets require global pharmaceutical companies to create and implement specific and custom strategies to succeed in these markets.
The whitepaper examines the current trends, requirements and outsourcing solutions for effective medical communication approach for the emerging markets.  www.sciformix.com/ROI.php |
DTC Advertising
As American as Acid Reflux
Over the counter drug advertising is less regulated than prescription drug marketing, and selling directly to consumers comes with the benefit of bypassing an expert middleman: your doctor. But companies should still promote with caution, writes Ben Comer
...Read More
Advertisement
Remember When Pharmaceutical Marketing Was Relatively Simple?
Between physicians, patients, pharmaceutical companies, pharmacists, marketing managers, payors and the FDA, the conversation isn't so simple anymore. Are current communications meeting the needs of all these stakeholders? Is there a fix? What's ahead? Find out how our industry's conversation has changed direction and scope, and if we have the tools to deal with this dynamic challenge.
See what pharmaceutical marketing expert Al Topin has to say on the subject in his insightful article and his video presentation.  Learn More
|
Global
UK to 'Export' the NHS: Just More Olympic Fever?
Following the misty-eyed portrayal of the National Health Service (NHS) in the London Olympic opening ceremony, the UK government has announced plans to export the NHS 'brand' around the world "to raise funds for patients at home and raise the international profile of the health service" ...Read More
Advertisement
The Impact of Comparative Effectiveness Research on the Healthcare Community
Live Webcast: Wednesday, August 29, 2012 at 11:00 AM Eastern
Register Free at  http://www.pharmexec.com/comparative
|
Orphan Drugs
Study 'Confirms Economic Viability' of Orphan Drugs
After achieving "blockbuster status" in 2011, generating over $50 billion, orphan drugs have the potential to generate as much lifetime revenue as drugs used for more common health conditions, according to a report from Thomson Reuters ...Read more |
|
|
 // INC Research, LLC (Raleigh, NC) announced that as part of a planned succession Chief Operating Officer Jamie Macdonald will become the company's next President and Chief Executive Officer. Chairman and CEO James T. Ogle will continue to serve as Chairman. Promoted to the role of COO is Alistair Macdonald, President, Clinical Development Services. Ogle, Jamie Macdonald and Alistair Macdonald will assume their new roles Jan. 1, 2013. // GlobalSubmit, Inc. (Philadelphia, PA) opened a new office in San Diego, CA, and hired Emily Onkka as Director of Project Management and Regulatory Operations. // Ariana Pharma (Paris, France and Cambridge, MA), a provider of "non-statistical" clinical data analysis technology, has appointed Dr. Mariana Kuras as its Chief Technology Officer. // Ipsos (New York, NY) appointed David Lansanah as its new Global Head of Product Testing. |
|
|
Advertisement
Meeting Global Patient Demand for Access to Medicines Prior to Approval and Launch
On-Demand Webcast
 http://pharmexec.com/demand |
|
|
|
|
 |
|
 |
|
 |
|
 |
|
 |
Should FDA be forced to make changes in how it regulates the drug industry?
|
|
|
|
